High impact information on PLGLB1

• Plasminogen-related protein B (PRP-B) closely resembles the N-terminal plasminogen activation peptide, which is released from plasminogen during conversion to plasmin [1].
• PRP-B and other antiangiogenic molecules may elicit metabolic perturbations in endothelial cells as well as perivascular mesenchymal cells such as smooth muscle cells and pericytes [1].
• Recombinant PRP-B is effective in promoting cell attachment of endothelial and smooth muscle cells, and antibody interference experiments reveal that the interaction of recombinant PRP-B with endothelial cells is mediated at least in part by alpha(v)-containing integrins [1].
• Inhibition of angiogenesis in vivo by PRP-B was demonstrated in the chicken chorioallantoic membrane assay [1].
• RNA samples obtained from cultured cell lines also demonstrated differing PRGB expression [2].

Other interactions of PLGLB1

• Reverse transcription-PCR analysis revealed that the PRGB expression varied widely among different tissues, while PLG was expressed only in the liver and kidney [2].
• CAT assays revealed that the promoter activity of PRGA was 3-fold that of plasminogen, while the activity of PRGB was 5-fold [3].

Analytical, diagnostic and therapeutic context of PLGLB1

• The PRGBP appears to measure knowledge of the current consensus on beliefs, goals, and practices in psychiatric rehabilitation, and is not a measure of these other responder characteristics [4].

References